Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | CA9 | Q16790 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9081951 | 0.83 | AXL (0.34) | CXCR2BCHEAXLTYRO3MERTK | |
| SCHEMBL27368413 | 0.82 | HPGD (0.37) | KLKB1PDE4B | |
| SCHEMBL21607865 | 0.81 | NOTUM (0.37) | CXCR2BCHEMEN1KMT2APDE4B | |
| SCHEMBL24509687 | 0.80 | POLB (0.35) | KLKB1MEN1KMT2APOLB | |
| SCHEMBL26970966 | 0.80 | BCHE (0.32) | BCHEKLKB1 | |
| SCHEMBL22978651 | 0.78 | CXCR2 (0.39) | CXCR2P2RX7CA1CA2CA9 | |
| SCHEMBL27942728 | 0.77 | BCHE (0.38) | BCHEIDO1CA1CA2CA9 | |
| SCHEMBL21608006 | 0.73 | RIPK1 (0.36) | BCHECA1CA2CA9 | |
| SCHEMBL3086653 | 0.73 | HTR2C (0.50) | MEN1KMT2A | |
| SCHEMBL18435973 | 0.73 | KLKB1 (0.32) | KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739694-A2 | MACROCYCLIC COMPOUNDS AND USE AS TYK2 INHIBITORS | Blossomhill Therapeutics, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4271674-B9 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12570642-B2 | GLP-IR modulating compounds | GILEAD SCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4691554-A2 | GLP-1R MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4271672-B1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4271674-B3 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250312352-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-10-09 | — | — | US | disclosed |
| EP-4520393-A2 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4271674-B1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2025010294-A2 | MACROCYCLIC COMPOUNDS AND USE AS TYK2 INHIBITORS | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| US-20140135339-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8680111-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680111-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20130252961-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2013132376-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| US-8324199-B2 | Pyridazine derivatives as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| EP-2265601-B1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | disclosed |
| EP-2265601-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009114677-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | F11, F12, TFPI2 | CXCR2 1326/4885BCHE 3051/4885IDO1 620/4885 |
| US-20250312352-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | CXCR2 1501/4885BCHE 1613/4885IDO1 4145/4885 |
| US-20130252961-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | ALK, ETV6, EML4 | CXCR2 1990/4885BCHE 2646/4885IDO1 4588/4885 |
| US-20140135339-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | ALK, ETV6, EML4 | CXCR2 1990/4885BCHE 2646/4885IDO1 4588/4885 |
| US-12570642-B2 | GLP-IR modulating compounds | GLP1R, GIPR, GPR119 | CXCR2 1016/4885BCHE 2023/4885IDO1 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.